Skip to main content
. 2023 Jan 30;13:1099550. doi: 10.3389/fonc.2023.1099550

Table 2.

PCR primers used in these studies.

PCR Primers
FAIRE and ChIP Primers
Locus Forward Sequence (5’-3’) Reverse Sequence (5’-3’)
P1 (screening site) AAGGAAGGAAGGGAGGGACACATAC CCTGTGAGTGTGACAGATTACTTGG
P7 (screening site) GGGTGACAGAGTAAGATCCTGTCAGA TGGGCGTGGTTCTCATGT
AURKAIP1 (+ control) TATACCCGCAGGTCCAGAATCGTT AATAGCTCTAGACGCTTCCGCCTT
BC006361 (- control) TTCTCCAACTTTGGAAGCCCAGGA TGTCTCCTTCTAGGCCCTCACAAT
JAK1 GGGAGGAATTGAAAGGAAGTGTGT TGTGAAACCTCGTCTGATCCACCCT
NR0B1 GCATCAGGAAGCCTGGATCCATTA GTATATACCAACACCCTTCCCTG
CAV1 AAGGAAGGAAGGAAGACCCT GTACAACGAATCCCTGTGACACAAA
MDM2 TGGATCTGAGGAGGAAATGTGCGT TAACTCATCCCTGTGCCTCTGCT
JAK1.2 GGAGACAGGCTCCAACACAGGAAA AAGTATCCCTCAAGTTGCCCTGCT
NKX2-2 TCTCTCCTTTCCATCGTTGGTGGT AGCACTCATCCTTAAGCCTCAACC
Negative Site 1 TGGATGCACAGAGAATGTCCACCT TGGTTCGTAAGTGACAGAGCCAGA
Expression Primers
Target Forward Sequence (5’-3’) Reverse Sequence (5’-3’)
EWS-FLI GCTATGGTCAACAAAGCAGCTATG TTGGCTAGGCGACTGCTGGT
GAPDH CTGACTTCAACAGCGACACC TAGCCAAATTCGTTGTCATACC